Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety (Q36407261)

14 August 2017

1 reference

title

Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety (English)

1 reference

14 August 2017

1 reference

Bruce Prenner

1

1 reference

14 August 2017

Kenneth Kim

2

1 reference

14 August 2017

Samir Gupta

3

1 reference

14 August 2017

Sauzanne Khalilieh

4

1 reference

14 August 2017

Bhavna Kantesaria

5

1 reference

14 August 2017

Prasarn Manitpisitkul

6

1 reference

14 August 2017

Richard Lorber

7

1 reference

14 August 2017

Zaiqi Wang

8

1 reference

14 August 2017

Barry Lutsky

9

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Expert Opinion on Drug Safety

14 August 2017

1 reference

14 August 2017

5

1 reference

14 August 2017

211-223

1 reference

14 August 2017

2

1 reference

Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organization. Executive summary of the workshop report. 7-10 December 1999, Geneva, Switzerland

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Quality of life in allergic rhinitis and asthma. A population-based study of young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Quality of life in adults and children with asthma and rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Quality of life in adults and children with allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Chronic urticaria: aetiology, management and current and future treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

The paradigm of type 1 and type 2 antigen-presenting cells. Implications for atopic allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Management and diagnostic guidelines for urticaria and angio-oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Desloratadine: A new, nonsedating, oral antihistamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

The safety and efficacy of desloratadine for the management of allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Safety of desloratadine syrup in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

First do no harm: managing antihistamine impairment in patients with allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Desloratadine: an update of its efficacy in the management of allergic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Second-generation antihistamines: the risk of ventricular arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Desloratadine: A preclinical and clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

A pharmacokinetic profile of desloratadine in healthy adults, including elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Pharmacogenetics and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Sedation, cognition, and antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Cardiac actions of antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Emerging safety issues regarding long-term usage of H(1)receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Second-generation antihistamines: actions and efficacy in the management of allergic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Switching prescription drugs to over the counter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Cardiotoxicity of new antihistamines and cisapride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

The pharmacologic profile of desloratadine: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Lack of clinically relevant interaction between desloratadine and erythromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.211

21 January 2018

Identifiers

DOI

10.1517/14740338.5.2.211

1 reference

14 August 2017

1 reference